A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 206 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
Estimated Study Start Date: February 1, 2021
Estimated Primary Completion Date: January 2023
Estimated Study Completion Date: January 2024
Arm:
- Experimental: Part1 Cohort1(AK112 + Pemetrexed or Paclitaxel+Carboplatin)
- Experimental: Part1 Cohort2(AK112 + Pemetrexed +Carboplatin)
- Experimental: Part1 Cohort3(AK112 + Docetaxel)
- Experimental: Part2 Cohort1(AK112 + Pemetrexed or Paclitaxel+Carboplatin)
- Experimental: Part2 Cohort2(Penpulimab(AK105) + Pemetrexed or Paclitaxel+Carboplatin)
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 206 |
| Estimated Study start date | 01 February 2021 |
| Estimated Study Completion Date | 01 January 2024 |